← Leaderboards
Sharie Haugabook
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsToxicologyInvestigational New Drug ApplicationUnited States Food And Drug AdministrationLeadDrug KineticsTherapeutics For Rare And Neglected DiseasesFormulationLungClinical TrialsCessation Of LifeSymptomsProteinsPre-ClinicalDoseAdultScientistOrganResearch Clinical TestingChronicBrainFatigueInvestigational DrugsCells
Grant awards (31)
Repurposing an EU Therapeutic for Hemoglobinopathies$757,464
ZIA · FY2025 · TR · contact PI
First-in-Class CD206 Agonist for Immunologically Cold Solid Organ Cancers$616,056
ZIA · FY2025 · TR · contact PI
Developing a Mitragynine Formulation to Conduct Rigorously Controlled Clinical Trials with a Kratom Alkaloid Extract$533,452
ZIA · FY2025 · TR · contact PI
Therapy to PreventBronchopulmonaryDysplasia (BPD)in PretermInfants$346,970
ZIA · FY2025 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$1,066,904
ZIA · FY2024 · TR · contact PI
Infusing Equity into Preclinical Research and Development$1,066,904
ZIA · FY2024 · TR · contact PI
First-in-Class CD206 Agonist for Immunologically Cold Solid Organ Cancers$1,066,904
ZIA · FY2024 · TR · contact PI
Developing a Mitragynine Formulation to Conduct Rigorously Controlled Clinical Trials with a Kratom Alkaloid Extract$1,066,904
ZIA · FY2024 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$1,668,330
ZIA · FY2023 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$3,025,490
ZIA · FY2022 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$1,785,026
ZIA · FY2022 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$2,585,805
ZIA · FY2021 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$1,623,279
ZIA · FY2021 · TR · contact PI
Development of Acoziborole for the Treatment of Human African Trypanosomiasis$1,071,030
ZIA · FY2021 · TR · contact PI
Novel Treatment for Hermansky-Pudlak Syndrome Pulmonary Fibrosis$1,071,030
ZIA · FY2021 · TR · contact PI
Novel Treatment for Hermansky-Pudlak Syndrome Pulmonary Fibrosis$2,846,332
ZIA · FY2020 · TR · contact PI
Development of Acoziborole for the Treatment of Human African Trypanosomiasis$1,732,658
ZIA · FY2020 · TR · contact PI
Targeted Bone Regeneration via Activation of Resident Stem Cells$1,377,569
ZIA · FY2020 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$3,125,463
ZIA · FY2019 · TR · contact PI
Novel Treatment for Hermansky-Pudlak Syndrome Pulmonary Fibrosis$2,405,066
ZIA · FY2019 · TR · contact PI
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis$1,546,330
ZIA · FY2019 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$3,369,075
ZIA · FY2018 · TR · contact PI
Novel Treatment for Hermansky-Pudlak Syndrome Pulmonary Fibrosis$2,405,066
ZIA · FY2018 · TR · contact PI
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis$1,035,100
ZIA · FY2018 · TR · contact PI
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis$2,853,144
ZIA · FY2017 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$2,453,144
ZIA · FY2017 · TR · contact PI
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis$1,765,116
ZIA · FY2016 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$1,765,116
ZIA · FY2016 · TR · contact PI
Treatment of Acid Ceramidase Deficiency$1,417,065
ZIA · FY2016 · TR · contact PI
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis$2,003,778
ZIA · FY2015 · TR · contact PI
Repurposing an EU Therapeutic for Hemoglobinopathies$2,003,778
ZIA · FY2015 · TR · contact PI